Primary hepatocellular carcinoma is one of the most common high-grade malignant tumors in the world. Its incidence ranks fifth among malignant tumors in China, and various therapeutic measures have poor curative effect. Pyruvate kinase type M2 is a key enzyme in the glycolytic pathway, and its abnormal expression in liver cancer is closely related to the proliferation, metastasis, diagnosis, treatment, prognosis, as well as drug and radiation resistance. Therefore, multi-pathway targeted regulation of pyruvate kinase type M2 use is expected to become a new direction for the treatment of primary liver cancer.原发性肝细胞癌是世界上常见、恶性程度很高的肿瘤之一,在中国恶性肿瘤中发病率排第5位,肝癌的各种治疗措施疗效不佳。M2型丙酮酸激酶作为糖酵解途径关键酶,它的异常表达与肝癌的增殖、转移、诊断、治疗及预后密切相关,与肝癌药物治疗的耐药和放射线抗拒也有关联,采用多种途径靶向调控肝癌细胞的M2型丙酮酸激酶,有望成为治疗原发性肝癌的一个新方向。.